News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alchemia and Dr. Reddy's Laboratories Ltd. (RDY) Expand Fondaparinux Marketing Collaboration


7/15/2010 8:31:08 AM

BRISBANE, Australia--(BUSINESS WIRE)--Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy’s Limited for marketing fondaparinux sodium for injection (the generic version of GlaxoSmithKline’s Arixtra®) in all territories outside of North America. This agreement does not in any way alter the existing arrangements between the companies for the manufacture and North American marketing of fondaparinux.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES